Summer can be a quiet time at academic institutions, but things have been highly eventful for MD Anderson’s Breast Medical Oncology Department in the past couple of months.
Two significant recruitments were announced; including Debu Tripathy, M.D., an enthusiastic new chair with an optimistic view of his department’s role in improving care and expanding treatment options for patients facing the disease. And another addition made...
MD Anderson Cancer Center has announced a partnership with Hospital Israelita Albert Einstein (HIAE) to pioneer multidisciplinary patient...
Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and...
New research from MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in determining whether older men with low-risk prostate cancer receive treatment for their disease, and if so, what type of treatment they receive.
The study, published in JAMA Internal Medicine, examined why active surveillance, which involves monitoring the cancer closely with prostate-specific antigen (PSA) blood...
Alas, the thankless pseudogene.
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives...
The main side effects of cytotoxic chemotherapy are notorious. But the side effects of newer, targeted molecular agents are less well known...
Dear colleagues,
I’m delighted to share with you Cancer Frontline from The University of Texas MD Anderson Cancer Center.
As...